|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: UBE2D4 |
Gene summary for UBE2D4 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | UBE2D4 | Gene ID | 51619 |
| Gene name | ubiquitin conjugating enzyme E2 D4 (putative) | |
| Gene Alias | HBUCE1 | |
| Cytomap | 7p13 | |
| Gene Type | protein-coding | GO ID | GO:0000209 | UniProtAcc | A0A024RA90 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51619 | UBE2D4 | LZE24T | Human | Esophagus | ESCC | 4.00e-08 | 2.66e-01 | 0.0596 |
| 51619 | UBE2D4 | P4T-E | Human | Esophagus | ESCC | 8.88e-06 | 2.29e-01 | 0.1323 |
| 51619 | UBE2D4 | P5T-E | Human | Esophagus | ESCC | 4.49e-02 | 6.17e-02 | 0.1327 |
| 51619 | UBE2D4 | P8T-E | Human | Esophagus | ESCC | 6.09e-06 | 1.15e-01 | 0.0889 |
| 51619 | UBE2D4 | P9T-E | Human | Esophagus | ESCC | 1.20e-06 | 2.02e-01 | 0.1131 |
| 51619 | UBE2D4 | P10T-E | Human | Esophagus | ESCC | 2.90e-25 | 4.02e-01 | 0.116 |
| 51619 | UBE2D4 | P11T-E | Human | Esophagus | ESCC | 3.86e-02 | 2.48e-01 | 0.1426 |
| 51619 | UBE2D4 | P12T-E | Human | Esophagus | ESCC | 9.21e-05 | 8.95e-02 | 0.1122 |
| 51619 | UBE2D4 | P15T-E | Human | Esophagus | ESCC | 1.17e-09 | 2.79e-01 | 0.1149 |
| 51619 | UBE2D4 | P16T-E | Human | Esophagus | ESCC | 6.31e-07 | 2.37e-01 | 0.1153 |
| 51619 | UBE2D4 | P19T-E | Human | Esophagus | ESCC | 8.50e-06 | 4.59e-01 | 0.1662 |
| 51619 | UBE2D4 | P20T-E | Human | Esophagus | ESCC | 4.79e-02 | 1.58e-01 | 0.1124 |
| 51619 | UBE2D4 | P21T-E | Human | Esophagus | ESCC | 2.03e-06 | 2.08e-01 | 0.1617 |
| 51619 | UBE2D4 | P22T-E | Human | Esophagus | ESCC | 4.66e-08 | 1.86e-01 | 0.1236 |
| 51619 | UBE2D4 | P23T-E | Human | Esophagus | ESCC | 1.30e-08 | 2.10e-01 | 0.108 |
| 51619 | UBE2D4 | P24T-E | Human | Esophagus | ESCC | 3.47e-04 | 9.43e-02 | 0.1287 |
| 51619 | UBE2D4 | P26T-E | Human | Esophagus | ESCC | 7.76e-08 | 2.43e-01 | 0.1276 |
| 51619 | UBE2D4 | P27T-E | Human | Esophagus | ESCC | 1.50e-07 | 1.43e-01 | 0.1055 |
| 51619 | UBE2D4 | P28T-E | Human | Esophagus | ESCC | 2.80e-11 | 2.53e-01 | 0.1149 |
| 51619 | UBE2D4 | P30T-E | Human | Esophagus | ESCC | 1.21e-07 | 2.10e-01 | 0.137 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000020917 | Esophagus | ESCC | protein polyubiquitination | 170/8552 | 236/18723 | 1.40e-16 | 1.09e-14 | 170 |
| GO:007093617 | Esophagus | ESCC | protein K48-linked ubiquitination | 55/8552 | 65/18723 | 8.42e-11 | 2.58e-09 | 55 |
| GO:007097912 | Esophagus | ESCC | protein K11-linked ubiquitination | 27/8552 | 29/18723 | 8.09e-08 | 1.39e-06 | 27 |
| GO:007053413 | Esophagus | ESCC | protein K63-linked ubiquitination | 44/8552 | 56/18723 | 4.84e-07 | 6.50e-06 | 44 |
| GO:000020921 | Liver | HCC | protein polyubiquitination | 151/7958 | 236/18723 | 1.90e-11 | 7.59e-10 | 151 |
| GO:007093621 | Liver | HCC | protein K48-linked ubiquitination | 52/7958 | 65/18723 | 6.70e-10 | 2.11e-08 | 52 |
| GO:00709791 | Liver | HCC | protein K11-linked ubiquitination | 24/7958 | 29/18723 | 1.04e-05 | 1.20e-04 | 24 |
| GO:007053411 | Liver | HCC | protein K63-linked ubiquitination | 39/7958 | 56/18723 | 3.63e-05 | 3.61e-04 | 39 |
| GO:000020910 | Oral cavity | OSCC | protein polyubiquitination | 150/7305 | 236/18723 | 1.59e-14 | 9.27e-13 | 150 |
| GO:00709369 | Oral cavity | OSCC | protein K48-linked ubiquitination | 53/7305 | 65/18723 | 2.47e-12 | 1.02e-10 | 53 |
| GO:00709793 | Oral cavity | OSCC | protein K11-linked ubiquitination | 26/7305 | 29/18723 | 2.05e-08 | 4.01e-07 | 26 |
| GO:00705344 | Oral cavity | OSCC | protein K63-linked ubiquitination | 37/7305 | 56/18723 | 3.74e-05 | 3.32e-04 | 37 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0412027 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
| hsa05131211 | Esophagus | ESCC | Shigellosis | 176/4205 | 247/8465 | 2.27e-12 | 4.01e-11 | 2.05e-11 | 176 |
| hsa0412036 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
| hsa05131310 | Esophagus | ESCC | Shigellosis | 176/4205 | 247/8465 | 2.27e-12 | 4.01e-11 | 2.05e-11 | 176 |
| hsa0414122 | Liver | HCC | Protein processing in endoplasmic reticulum | 146/4020 | 174/8465 | 7.34e-24 | 2.46e-21 | 1.37e-21 | 146 |
| hsa0412041 | Liver | HCC | Ubiquitin mediated proteolysis | 110/4020 | 142/8465 | 1.67e-13 | 3.74e-12 | 2.08e-12 | 110 |
| hsa0513142 | Liver | HCC | Shigellosis | 150/4020 | 247/8465 | 1.53e-05 | 1.04e-04 | 5.81e-05 | 150 |
| hsa0414132 | Liver | HCC | Protein processing in endoplasmic reticulum | 146/4020 | 174/8465 | 7.34e-24 | 2.46e-21 | 1.37e-21 | 146 |
| hsa0412051 | Liver | HCC | Ubiquitin mediated proteolysis | 110/4020 | 142/8465 | 1.67e-13 | 3.74e-12 | 2.08e-12 | 110 |
| hsa0513152 | Liver | HCC | Shigellosis | 150/4020 | 247/8465 | 1.53e-05 | 1.04e-04 | 5.81e-05 | 150 |
| hsa0414130 | Oral cavity | OSCC | Protein processing in endoplasmic reticulum | 143/3704 | 174/8465 | 6.82e-26 | 2.28e-23 | 1.16e-23 | 143 |
| hsa0412020 | Oral cavity | OSCC | Ubiquitin mediated proteolysis | 105/3704 | 142/8465 | 1.83e-13 | 4.37e-12 | 2.23e-12 | 105 |
| hsa0513130 | Oral cavity | OSCC | Shigellosis | 150/3704 | 247/8465 | 3.96e-08 | 3.12e-07 | 1.59e-07 | 150 |
| hsa04141113 | Oral cavity | OSCC | Protein processing in endoplasmic reticulum | 143/3704 | 174/8465 | 6.82e-26 | 2.28e-23 | 1.16e-23 | 143 |
| hsa04120110 | Oral cavity | OSCC | Ubiquitin mediated proteolysis | 105/3704 | 142/8465 | 1.83e-13 | 4.37e-12 | 2.23e-12 | 105 |
| hsa05131113 | Oral cavity | OSCC | Shigellosis | 150/3704 | 247/8465 | 3.96e-08 | 3.12e-07 | 1.59e-07 | 150 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| UBE2D4 | SNV | Missense_Mutation | rs553718857 | c.388N>A | p.Asp130Asn | p.D130N | Q9Y2X8 | protein_coding | tolerated_low_confidence(0.16) | benign(0.054) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| UBE2D4 | SNV | Missense_Mutation | novel | c.196A>C | p.Lys66Gln | p.K66Q | Q9Y2X8 | protein_coding | deleterious_low_confidence(0.01) | benign(0.346) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| UBE2D4 | SNV | Missense_Mutation | novel | c.115G>T | p.Gly39Cys | p.G39C | Q9Y2X8 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.997) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| UBE2D4 | SNV | Missense_Mutation | novel | c.314N>T | p.Ser105Phe | p.S105F | Q9Y2X8 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.984) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| UBE2D4 | SNV | Missense_Mutation | novel | c.203N>T | p.Ala68Val | p.A68V | Q9Y2X8 | protein_coding | tolerated_low_confidence(0.14) | benign(0.005) | TCGA-AX-A3G9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
| UBE2D4 | SNV | Missense_Mutation | c.216N>C | p.Lys72Asn | p.K72N | Q9Y2X8 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.928) | TCGA-B5-A11N-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| UBE2D4 | SNV | Missense_Mutation | novel | c.175N>T | p.Asp59Tyr | p.D59Y | Q9Y2X8 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.989) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| UBE2D4 | SNV | Missense_Mutation | rs766962108 | c.269G>A | p.Arg90Gln | p.R90Q | Q9Y2X8 | protein_coding | tolerated_low_confidence(0.06) | benign(0.039) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| UBE2D4 | SNV | Missense_Mutation | c.216A>C | p.Lys72Asn | p.K72N | Q9Y2X8 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.928) | TCGA-D1-A17Q-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| UBE2D4 | SNV | Missense_Mutation | novel | c.61N>C | p.Cys21Arg | p.C21R | Q9Y2X8 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.982) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |